

COPY OF PAPERS
ORIGINALLY FILED

(Modified) PTO/SB/21 (6-98)

Approved for use through 09/30/2000. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Please type a plus sign (+) inside this box → +

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

1644+

TRANSMIT PALE
FORM JUL 29 2002

(to be used for all correspondence after initial filing)



		Application Number	09/601,971
		Filing Date	March 29, 1999
		First Named Inventor	RADEMACHER, Thomas
		Group Art Unit	1644
		Examiner Name	Amy M. Decloux
Total Number of Pages in This Submission	5	Attorney Docket Number	1012-010000US

RECEIVED
AUG 06 2002

TECH CENTER 1600/2900

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Receipt acknowledgment postcard
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Small Entity Statement	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
Authorization to Charge Deposit Account Please charge Deposit Account No. 50-0893 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.		
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Irene Pleasure, Reg. No. 45,506 Quine Intellectual Property Law Group P.C.
Signature	
Date	July 23, 2002

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: July 23, 2002

Typed or printed name	Amelia GROTH
Signature	
Date	July 23, 2002



COPY OF PAPERS
ORIGINALLY FILED

11
gad

RECEIVED

AUG 06 2002

TECH CENTER 1600/2900

I hereby certify that this correspondence is being
deposited with the United States Postal Service as
first class mail in an envelope addressed to:
Assistant Commissioner for Patents,
Washington, D.C. 20231, on July 23, 2002

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

By _____

Amelia Groth
Amelia Groth

Attorney Docket No. 1012-010000US
Client Ref. No. SJK/BP5868062

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:
RADEMACHER, Thomas William, et al.

Application No.: 09/601,971

Filed: March 29, 1999

For: IPG ANTAGONISTS FOR THE
TREATMENT OF CONDITIONS
INVOLVING MAST CELLS,
BASOPHILS, AND EOSINOPHILS

Examiner: Amy M. DeCloux

Art Unit: 1644

RESPONSE TO REVISED RESTRICTION REQUIREMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This Communication is in response to the Revised Restriction Requirement mailed May 20, 2002, and having a shortened statutory period for reply of one month. In the above-identified application, claims 1-23 are currently pending. Reconsideration of the application is requested in light of the remarks below.

The following documents are submitted herewith:

- 1) A transmittal sheet;
- 2) A petition for extension of time through the present date; and,
- 3) A receipt indication postcard.

RESPONSE TO REVISED RESTRICTION REQUIREMENT

Thomas William Rademacher et al.
Application No.: 09/601,971
Page 2

Applicants elect Examiner's Group I (claims 1-9 and 15-20). In addition, since Group I was elected, Applicants have been requested (a) to select a specific type of antagonist, (b) to select a specific cell, (c) to select a specific condition or disorder, and (d) to select a specific allergy, such as one recited in claim 15.

In response to the election requirement, Applicants elect to prosecute inhibitors of GPI-PLD as a specific type of antagonist, mast cells as a specific cell type, allergy as a specific condition or disorder and seasonal allergy as a specific allergy.

Applicants note that the election above is without traverse, on the understanding that the procedures specified in the MPEP under §§ 809.02 are intended to be followed with respect to the election of species requirement.

Conclusion

If a telephone conference would expedite prosecution of this application, the Examiner is invited to telephone the undersigned at (510) 337-7871.

Respectfully submitted,



Irene T. Pleasure, J.D., Ph.D.
Reg. No. 45,506

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.
P.O. BOX 458
Alameda, CA 94501
(510) 337-7871
Fax (510) 337-7877